Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07136428) titled 'Asciminib in HER2+ Breast Cancer Brain Metastases' on Aug. 15.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Duke University

Condition: HER2+ Metastatic Breast Cancer

Intervention: Combination Product: Asciminib and Trastuzumab

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: November 1, 2025

Target Sample Size: 42

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07136428

Published by HT Digital Content Services with permission f...